1. Home
  2. CIEN vs NTRA Comparison

CIEN vs NTRA Comparison

Compare CIEN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ciena Corporation

CIEN

Ciena Corporation

HOLD

Current Price

$200.42

Market Cap

28.3B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.06

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIEN
NTRA
Founded
1992
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3B
27.0B
IPO Year
1997
2015

Fundamental Metrics

Financial Performance
Metric
CIEN
NTRA
Price
$200.42
$244.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
16
Target Price
$152.36
$227.69
AVG Volume (30 Days)
3.5M
1.7M
Earning Date
12-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
3.32
N/A
EPS
0.98
N/A
Revenue
$4,541,635,000.00
$2,116,676,000.00
Revenue This Year
$19.58
$32.77
Revenue Next Year
$16.89
$16.51
P/E Ratio
$205.91
N/A
Revenue Growth
12.97
38.17
52 Week Low
$49.21
$125.38
52 Week High
$214.17
$245.59

Technical Indicators

Market Signals
Indicator
CIEN
NTRA
Relative Strength Index (RSI) 58.28 80.03
Support Level $186.39 $233.67
Resistance Level $209.19 $240.18
Average True Range (ATR) 10.53 7.39
MACD -0.80 0.68
Stochastic Oscillator 79.72 97.49

Price Performance

Historical Comparison
CIEN
NTRA

About CIEN Ciena Corporation

Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: